-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
HIV-1 inhibitor-3
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/1612841-22-1.gif)
| Category | Human immunodeficiency Virus (HIV) |
| CAS | 1612841-22-1 |
| Description | HIV-1 inhibitor-3 is an inhibitor of HIV infection. (Extracted from patent US2018360927) |
Product Information
| Synonyms | 1-((2R,3R,4S,5S)-3,5-Difluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione; 1-(2-Deoxy-2,4-difluoro-beta-D-ribofuranosyl)uracil; Uridine, 2'-deoxy-2'-fluoro-4'-C-fluoro- |
| IUPAC Name | 1-[(2R,3R,4S,5S)-3,5-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione |
| Molecular Weight | 264.18 |
| Molecular Formula | C9H10F2N2O5 |
| Canonical SMILES | C1=CN(C(=O)NC1=O)C2C(C(C(O2)(CO)F)O)F |
| InChI | InChI=1S/C9H10F2N2O5/c10-5-6(16)9(11,3-14)18-7(5)13-2-1-4(15)12-8(13)17/h1-2,5-7,14,16H,3H2,(H,12,15,17)/t5-,6+,7-,9-/m1/s1 |
| InChIKey | QMLNPJRBOJRGPS-JVZYCSMKSA-N |
| Purity | ≥95% |
| Density | 1.7±0.1 g/cm3 |
| Solubility | Soluble in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| Complexity | 418 |
| Exact Mass | 264.05577775 |
| Target | HIV |
| XLogP3-AA | -1 |
